RARebecca A. Abelman

Rebecca A. Abelman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca A. Abelman has a total of 161 co-authors. Here are the top co-authors by number of shared publications:

  • Laurence Huang

    Department of Medicine, University of California San Francisco, San Francisco, CA 94143 USA

    5 shared publications
  • Carl Grunfeld

    Department of Medicine University of California San Francisco San Francisco California USA

    3 shared publications
  • Emmanuel Musisi

    Infectious Diseases Research Collaboration, Kampala, Uganda

    3 shared publications
  • Fan Xia

    Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94143 USA

    3 shared publications
  • Ingvar Sanyu

    Infectious Diseases Research Collaboration, Kampala, Uganda

    3 shared publications
  • Jake Branchini

    Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America

    3 shared publications

Latest Publications

  • Open Access

    Syndemic burden, menopause, and cardiovascular risk among midlife and older women with and without HIV

    by Yue Pan, Emily M. Cherenack, Daniel J. Feaster, Yawen Lu, BreAnne Young, Kayla V. McNeely, Tracey Wilson, Brandilyn A. Peters, Emily B. Levitan, Caitlin Moran, et al.

    Midlife and older women living with HIV often carry several co-occurring social and behavioral stressors, and how that accumulated burden relates to cardiovascular risk is not well described. We examined whether cumulative syndemic burden was associated with estimated 10-year risk of atherosclerotic cardiovascular disease among women aged 45 years and older, and whether menopause stage modified it. Data came from the MACS/WIHS Combined Cohort Study, a multisite United States cohort, for visits between October 2020 and March 2025. The full sample included 1,993 women, 1,446 of them living with HIV; a secondary sample of 1,063 women virally suppressed at baseline contributed 4,009 visits. Syndemic burden was the sum of six conditions: elevated depressive symptoms, current tobacco use, hazardous alcohol use, recent stimulant use, physical inactivity, and material insecurity. Ten-year cardiovascular risk was estimated with the Pooled Cohort Equations and modeled with linear mixed-effects models with random intercepts; random forest classifiers were trained separately to predict high estimated risk (7.5 percent or greater). Median age was 56 years, 63 percent were non-Hispanic Black, and 57 percent reported two or more syndemic conditions. Each additional syndemic condition was associated with a 0.40-point higher estimated risk score (95 percent confidence interval 0.01 to 0.78; p=0.043), and postmenopausal status with a 1.3-point higher score than premenopause (0.39 to 2.3; p=0.006). The syndemic burden by menopause stage interaction was not significant overall (p=0.2), although an exploratory signal was present among virally suppressed women (0.50; p=0.079). The classifiers discriminated moderately (areas under the curve 0.727 and 0.704); serum creatinine, body mass index, syndemic burden, and postmenopausal status ranked among the most important predictors. Syndemic burden and reproductive aging were each independently and modestly associated with higher estimated cardiovascular risk, supporting joint assessment of both in risk stratification for midlife women with and without HIV.

  • Frailty Is Associated With Lower Urinary Tract Symptoms in Adults With and Without HIV

    by Rebecca A. Abelman, Yifei Ma, Joseph B. Margolick, Kristine M. Erlandson, Meredith Greene, Anne M. Suskind, Tonya Taylor, Charles R. Rinaldo, Michelle Floris‐Moore, Kara W. Chew, et al.

    Background: Frailty is a risk factor for lower urinary tract symptoms (LUTS) in older adults. People with HIV (PWH) have a heightened frailty burden, but the association of HIV and frailty with LUTS in people with and at risk for HIV is unknown. Methods: Data from 1356 PWH (505 men, 851 women) and 820 without HIV (419 men, 401 women) enrolled in the MACS‐WIHS Combined Cohort Study who completed the Lower Urinary Tract Dysfunction Research Network 10‐Item Symptom Index (LURN SI‐10) from 10/2021 to 9/2022 were included. Frailty was determined using the Fried frailty phenotype (robust, pre‐frail, and frail). Regression models stratified by sex evaluated the cross‐sectional associations of HIV and frailty with LUTS severity, urgency urinary incontinence (UUI), and overactive bladder (OAB). Due to low prevalence in men, mixed urinary incontinence (MUI) was analyzed only in women. Effect modification by sex and HIV was tested using the interaction terms with frailty. Results: Mean age was 56 years (SD 11), and 58% of participants were Black. For women, 53% were pre‐frail and 23% were frail. For men, 46% were pre‐frail and 13% were frail. There was no association of HIV with LUTS. Among women, 21% reported UUI, 61% reported OAB, and 14% reported MUI at least weekly. Compared to robust women, frail women had higher LURN SI‐10 scores (absolute difference = 3.3 (95% CI: 2.3, 4.3)). Similarly, frail men had higher LURN SI‐10 scores than robust men (absolute difference = 1.6 (95% CI: 0.4, 2.9)). Frailty was associated with greater odds of UUI and OAB in women and men, and MUI in women. There was no evidence of effect modification by sex. Conclusions: LUTS are common in people with and at‐risk for HIV and are more severe among those who are frail. More research is needed to investigate the sex‐independent mechanisms that underlie frailty and LUTS in this population.

  • Menopause Is Associated With Lower Lung Function in Women With and Without HIV

    by Rebecca A. Abelman, Fan Xia, M. Bradley Drummond, Mirjam-Colette Kempf, Maria L. Alcaide, Lauren F. Collins, Amanda Blair Spence, Brandilyn A. Peters, Deborah Gustafson, Ken M. Kunisaki, et al.


  • Open Access

    Recurrent episodes of pneumonia are associated with worse lung function in people with HIV

    by Sven J. Walderich, Jessica Fitzpatrick-Collins, Aryana Bates, Michelle H. Zhang, Jake Branchini, Kendall Gardner, Sharvari Bhide, Amanda Jan, Rebecca Abelman, Katerina L. Byanova, et al.

    Background: HIV is associated with a decreased diffusing capacity for carbon monoxide (DLco), decreased spirometry, and an increased risk for developing obstructive lung disease, even in never-smokers. Pneumonia is a risk factor for impaired pulmonary function in people with HIV (PWH), but whether recurrent pneumonia results in a commensurate decline in lung function is unknown. Methods: We reviewed the electronic medical records and PFT data for PWH in San Francisco, CA. Participants were categorized by number of pneumonias since HIV diagnosis. We analyzed the association between the number of pneumonias and lung function using linear and logistic regression models after adjusting for substance use and HIV-associated factors. Results: Among 259 participants, the mean age was 51 years, 15% were female, and 42% were current smokers. One hundred (39%) participants had no prior pneumonia, 52 (20%) had 1 pneumonia, 50 (19%) had 2 pneumonias and 57 (22%) had ≥3 pneumonias. Multiple pneumonias were associated with a stepwise decline in FEV1, FVC, and DLCO %predicted (p-trend Pneumocystis pneumonia during their first episode. Conclusion: In PWH with a high prevalence of inhalational substance use, recurrent episodes of pneumonia are associated with a commensurate decline in lung function in PWH characterized by airflow obstruction and diffusion limitations. While further studies are needed to elucidate the underlying mechanism, this work highlights the importance of preventing recurrent pneumonia in PWH in order to preserve lung function.

  • Open Access

    Age modifies the association between sex and the plasma inflammatory proteome in treated HIV

    by Rebecca A. Abelman, Samuel R. Schnittman, Natalia Faraj Murad, Adam B. Olshen, Gabriele B. Beck-Engeser, Noah Aquino, Gabrielle C. Ambayec, Edward R. Cachay, Joseph J. Eron, Michael S. Saag, et al.

    BACKGROUND: Among antiretroviral therapy–suppressed (ART-suppressed) people with HIV (PWH), women have higher levels of some inflammatory markers than men, but the effect of sex on the inflammatory proteome, and whether age modifies these differences, remain unclear. METHODS: Plasma inflammatory protein levels were assessed in ART-suppressed PWH from the Center for AIDS Research Network of Integrated Clinical Systems. The relationship between sex and plasma proteins — including 22 interferon-α response pathway proteins — was assessed, adjusting for confounders and assessing interactions by age. RESULTS: Of 922 participants, 162 (18%) were female. The median age was 47, above which the majority of women had undetectable plasma anti-Müllerian hormone levels, a biomarker of ovarian reserve. Age modified the influence of sex on the inflammatory proteome. Older age (>47) was associated with greater increases among women than men in 194 proteins. Interferon-α response proteins were higher in men in those ≤ 47 but higher in women in those > 47 (interaction P < 0.001). Among the 131 proteins associated with mortality risk ( q < 0.05), only 5 differed by sex among those ≤ 47, while 79 differed by sex in those > 47, with nearly all being higher in women. Women had decreased mortality than men ≤ 47 ( P < 0.001) but had similar mortality > 47 ( P = 0.84). CONCLUSION: The menopausal transition appears to increase systemic type I interferon responses and inflammation in women with HIV, which may contribute to a loss of female advantage in mortality. FUNDING: NIH National Heart, Lung, and Blood Institute; National Institute of Neurological Disorders and Stroke; National Institute of Allergy and Infectious Diseases.


  • Open Access

    Spectrum From Acute Myocardial Injury to Infarction Among People With Human Immunodeficiency Virus Seeking Emergency Care in the United States: Presentations, Provider Responses, and Clinical Outcomes

    by Rebecca A Abelman, Brian M Mugo, Claudia G Durbin, Sophia Campbell, Sayon Dutta, Dustin McEvoy, Emily S Lau, Sophia Zhao, Sara L Stockman, Sarah M Chu, et al.

    Background: In the United States (US), people with human immunodeficiency virus (PWH) have an increased risk of myocardial infarction, including type 1 myocardial infarction (T1MI) and type 2 myocardial infarction (T2MI). Presentations and clinical trajectories of PWH experiencing acute myocardial injury (AMI) have not been well characterized. Methods: Leveraging electronic health records (EHRs) from a US academic medical center, we identified PWH presenting to the emergency department from 2015 to 2019 with a troponin T ≥99th percentile. Presentations were adjudicated as AMI, T2MI, or T1MI. Clinical presentations, provider-level responses, and ensuing clinical outcomes (post–index event) were compared. Among PWH with AMI or T2MI, observed incidence of ensuing major adverse cardiovascular event (MACE) was evaluated using the cumulative incidence function by Aalen estimator. Adjusted cause-specific Cox proportional hazards models were used to assess the association between presentation type and ensuing MACE. Results: Among 79 cases analyzed, presentations of AMI and T2MI were more common than T1MI (29.1% and 64.6% vs 6.3%, respectively). Infection represented the most common event trigger for AMI and T2MI. Among PWH presenting with AMI versus T2MI, there was no difference in risk of ensuing MACE (adjusted hazard ratio, 1.14 [95% confidence interval, .48–2.71]). The proportion of cases of AMI versus T2MI not categorized with any cardiovascular disease–related diagnosis code differed significantly (91% vs 53%, P = .001). Conclusions: Among US PWH presenting for emergency care, AMI was infrequently coded in the EHR. AMI and T2MI were associated with comparable rates of ensuing MACE. Enhanced recognition/documentation of AMI among PWH will facilitate development of preventive care approaches.

  • Geriatric syndromes in women living with HIV

    by Rebecca Abelman

    Purpose of review: To describe the current research on geriatric syndromes in women with HIV (WWH) and their potential clinical implications. Recent findings: Geriatric syndromes are multifactorial age-related changes that are associated with functional decline. In those without HIV, many geriatric syndromes have a higher prevalence in women. In those with HIV, there are important sex differences in frailty trajectories and sarcopenia. WWH demonstrate an increased risk for osteoporosis and cognitive decline compared to men and to women without HIV. Urinary incontinence and social isolation are also prevalent in WWH and impact quality of life. Several of these geriatric syndromes are modified by the menopausal transition in WWH. Summary: Research is needed to identify the predictors of geriatric syndrome development and progression in WWH. These findings could inform timing of screening or intervention strategies for aging WWH.


  • Menopause is associated with faster increases in insulin resistance in women with HIV

    by Rebecca A. Abelman, Yifei Ma, C. Christina Mehta, Qian Yang, Fan Xia, James B. Brock, Maria L. Alcaide, Anjali Sharma, Michelle Floris-Moore, Elizabeth Topper, et al.

    Background: Switching to an integrase strand transfer inhibitor (INSTI) during the menopausal transition has been associated with accelerated increases in visceral obesity, a risk factor for insulin resistance. Whether switching to an INSTI modifies the association of HIV and menopause with insulin resistance is unknown. Methods: From 2006 to 2019, 389 nonpregnant women with HIV (WWH) [133 who switched to an INSTI (INSTI+); 256 who did not switch (INSTI−)] and 334 women without HIV from the Women's Interagency HIV study without diabetes or hepatitis C virus were included in the analysis. Mixed effect models evaluated the change in insulin resistance estimated through log HOMA-IR by HIV status by menopausal phase. We then compared trajectories by INSTI group. Menopausal phase was determined by anti-Müllerian hormone, a biomarker of ovarian reserve. Results: Compared to women without HIV, INSTI+ WWH in premenopause had nonstatistically significant faster annual increases in HOMA-IR [difference in slope: 7.03%; 95% confidence interval (CI): −4.99 to 20.58] whereas INSTI− WWH had nonstatistically significantly faster annual decreases [−1.01% (95% CI: −7.34 to 5.75)]. In late perimenopause, INSTI+ and INSTI− had 4.87% (95% CI: −3.59 to 14.06) and 4.38% (95%CI: −3.10 to 12.44) nonstatistically significantly faster annual increases in HOMA-IR, respectively. In menopause, INSTI+ and INSTI− WWH had 9.18% (95% CI: 1.60 to 17.33) and 11.28% (95% CI: 3.27 to 19.91) statistically significant faster annual increases in HOMA-IR than women without HIV. There was no statistically significant difference between INSTI+ and INSTI− in any menopausal phase. Conclusion: Regardless of switching to an INSTI or not, WWH in late perimenopause and menopause have faster increases in insulin resistance when compared to women without HIV. Diabetes screening and prevention in midlife WWH is imperative.

  • Brief Report: Sex and HIV Modify Immune Activation Biomarkers in Ugandans Post-Tuberculosis

    by Rebecca A. Abelman, Jessica PhD. Fitzpatrick, Josephine Mph Zawedde, Gabriele B.Sc Beck-Engeser, Ingvar Sanyu, Florence B.S. Marzan, Patrick Byanyima, Gabrielle C. B.S Ambayec, Sylvia Kaswabuli, Emmanuel Musisi, et al.

    Background: Although there are sex and HIV differences in tuberculosis (TB) prevalence, the underlying mechanisms are incompletely understood. Few studies have evaluated whether sex and HIV modify the inflammatory response to TB. Methods: Adults with pulmonary TB with and without HIV in Kampala, Uganda had 12 immune activation biomarkers measured at TB diagnosis and at completion of therapy. Associations between biomarkers and sex were assessed using multivariable regression models at baseline and follow-up after adjusting for age, HIV status, and AFB smear grade. Given evidence of sex–HIV interaction in several biomarkers, models were stratified by HIV status. Results: Overall, 151 participants were included and 74 (49%) were female. Forty-nine (32%) participants had HIV; 21 (43%) of those with HIV were female. At baseline, biomarkers were overall higher in men, whereas at follow-up, suPAR (P < 0.001) and sCD163 were higher in women (P = 0.02) and IL-6 (P = 0.01) and IFABP (P = 0.02) were higher in men. After stratifying by HIV status, at baseline, most of the biomarkers were higher in men without HIV and there were no sex differences in those with HIV. At follow-up, women without HIV had higher levels of suPAR (P = 0.01) and sCD163 (P = 0.051). Women with HIV had higher levels of suPAR, C-reactive protein, and IP-10 (P < 0.05 for all); no other sex differences were observed. Conclusions: Among adults with pulmonary TB in Uganda, men had greater immune activation than women only in the absence of HIV. After treatment, women tended to have more immune activation than men in the setting of HIV.


  • Switch to Integrase Strand Transfer Inhibitors During the Menopausal Transition Is Associated With Accelerated Body Composition Change in Women With HIV

    by Rebecca A Abelman, Yifei Ma, C Christina Mehta, Qian Yang, Fan Xia, James B Brock, Maria Alcaide, Anjali Sharma, Michelle Floris-Moore, Elizabeth Topper, et al.

    Background: Integrase strand transfer inhibitors (INSTIs) and the menopausal transition have been associated with body composition changes in women with human immunodeficiency virus (WWH), but their interaction is unknown. Methods: From 2006 to 2019, 1131 virally-suppressed WWH (419 who switched to INSTI [INSTI+]; 712 who did not switch [INSTI–]) and 887 women without HIV (WWOH) from the Women's Interagency HIV Study were included. Mixed-effects models were used to evaluate change in waist circumference (WC) and body mass index (BMI) by menopausal phase defined using anti-Müllerian hormone, a biomarker of ovarian reserve. Results: During premenopause, WWH had increases in WC (INSTI+: 0.01 cm per 6 months [95% confidence interval {CI}: −.29 to .32] and INSTI−: 0.22 cm per 6 months [95% CI: −.01 to .44]) that were not statistically significantly different from WWOH; there was also little difference by INSTI status. In late perimenopause, INSTI+ had faster increases in WC (0.37 cm per 6 months [95% CI: .15–.60]) while INSTI− had smaller increases (0.14 cm per 6 months [95% CI: −.06 to .34]) compared to WWOH. In menopause, INSTI+ had faster increases, peaking at 43 months then declining, while INSTI− had smaller increases (0.14 cm per 6 months [95% CI: −.02 to .30]). Compared to INSTI−, in late perimenopause, INSTI+ had 0.26 cm per 6 months (95% CI: .02–.50) faster linear increases in WC and in menopause, INSTI+ was associated with faster increases, peaking at 41 months. Conclusions: Switching to an INSTI-based regimen during late perimenopause and menopause is associated with faster increases in WC when compared to women who did not switch. Menopausal status should be considered when switching to an INSTI.